Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Britannia Pharmaceuticals Ltd.
• Treatments: Apomorphine

Criteria

Inclusion Criteria:

• 1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day

Exclusion Criteria:

• hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females